Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic statusHIROTA, Takeshi; LEIRI, Ichiro; HIGUCHI, Shun et al.Human molecular genetics (Print). 2004, Vol 13, Num 23, pp 2959-2969, issn 0964-6906, 11 p.Article

Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteersSHAIK, M. Naveed; LABADIE, Robert R; RUDIN, Dan et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 2, pp 411-418, issn 0344-5704, 8 p.Article

Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug developmentSINZ, Michael W.Drug metabolism reviews (Softcover ed.). 2013, Vol 45, Num 1, pp 3-14, issn 0360-2532, 12 p.Article

Prédiction quantitative des interactions médicamenteuses impliquant les cytochromes 3A4 et 2D6: approche in vivo : Interactions médicamenteuses: quoi de neuf ? = Quantitative prediction of CYP3A4 and CYP2D6-mediated drug-drug interactions based on in vivo dataGOUTELLE, S; TOD, M.La Lettre du pharmacologue (Boulogne). 2012, Vol 26, Num 2, pp 57-62, issn 0984-452X, 6 p.Article

Comparative Study of the Effects of Antituberculosis Drugs and Antiretroviral Drugs on Cytochrome P450 3A4 and P-GlycoproteinHORITA, Yasuhiro; DOI, Norio.Antimicrobial agents and chemotherapy. 2014, Vol 58, Num 6, pp 3168-3176, issn 0066-4804, 9 p.Article

Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction DataEINOLF, H. J; CHEN, L; ZHAO, P et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 2, pp 179-188, issn 0009-9236, 10 p.Article

Clobazam Therapeutic Drug Monitoring: A Comprehensive Review of the Literature With Proposals to Improve Future StudiesDE LEON, Jose; SPINA, Edoardo; DIAZ, Francisco J et al.Therapeutic drug monitoring. 2013, Vol 35, Num 1, pp 30-47, issn 0163-4356, 18 p.Article

Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and RifapentineWILLIAMSON, Beth; DOOLEY, Kelly E; YUAN ZHANG et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 12, pp 6366-6369, issn 0066-4804, 4 p.Article

Semi-physiologically based pharmacokinetic modeling of paclitaxel metabolism and in silico-based study of the dynamic sensitivities in pathway kineticsFRANSSON, Martin N; BRUGARD, Jan; ARONSSON, Peter et al.European journal of pharmaceutical sciences. 2012, Vol 47, Num 4, pp 759-767, issn 0928-0987, 9 p.Article

Genetic epidemiology of induced CYP3A4 activityRAHMIOGLU, Nilufer; HEATON, James; AHMADI, Kourosh R et al.Pharmacogenetics and genomics (Print). 2011, Vol 21, Num 10, pp 642-651, issn 1744-6872, 10 p.Article

Development of novel furanocoumarin dimers as potent and selective inhibitors of cyp3a4ROW, E; BROWN, S. A; STACHULSKI, A. V et al.Drug metabolism and disposition. 2006, Vol 34, Num 2, pp 324-330, issn 0090-9556, 7 p.Article

Role of cytochrome B₅ in modulating peroxide-supported CYP3A4 activity : Evidence for a conformational transition and cytochrome P450 heterogeneityKUMAR, Santosh; DAVYDOV, Dmitri R; HALPERT, James R et al.Drug metabolism and disposition. 2005, Vol 33, Num 8, pp 1131-1136, issn 0090-9556, 6 p.Article

Mitotane has a strong and a durable inducing effect on CYP3A4 activityVAN ERP, Nielka P; GUCHELAAR, Henk-Jan; PLOEGER, Bart A et al.European journal of endocrinology. 2011, Vol 164, Num 4, pp 621-626, issn 0804-4643, 6 p.Article

Differential regulation of CYP3A4 and CYP3A7 by dimethylsulfoxide in primary human hepatocytesWILKENING, Stefan; BADER, Augustinus.Basic & clinical pharmacology & toxicology (Print). 2004, Vol 95, Num 2, pp 92-93, issn 1742-7835, 2 p.Article

The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variabilityHUAN QIU; MATHÄS, Marianne; NESTLER, Sebastian et al.Pharmacogenetics and genomics (Print). 2010, Vol 20, Num 3, pp 167-178, issn 1744-6872, 12 p.Article

CYP3 phylogenomics : evidence for positive selection of CYP3A4 and CYP3A7HUAN QIU; TAUDIEN, Stefan; HERLYN, Holger et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 1, pp 53-66, issn 1744-6872, 14 p.Article

An in vitro bioassay for xenobiotics using the SXR-Driven human CYP3A4/lacz reporter geneLEE, Mi R; KIM, Yeon J; CHO, Jung S et al.International journal of toxicology. 2003, Vol 22, Num 3, pp 207-213, issn 1091-5818, 7 p.Article

Time-dependent inhibition of CYP3A4 by sertraline, a selective serotonin reuptake inhibitorMASUBUCHI, Yasuhiro; KAWAGUCHI, Yuki.Biopharmaceutics & drug disposition. 2013, Vol 34, Num 8, pp 423-430, issn 0142-2782, 8 p.Article

Fluoxetine- and Norfluoxetine-Mediated Complex Drug―Drug Interactions: In Vitro to In Vivo Correlation of Effects on CYP2D6, CYP2C19, and CYP3A4SAGER, J. E; LUTZ, J. D; FOTI, R. S et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 6, pp 653-662, issn 0009-9236, 10 p.Article

The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly AustraliansKERR, K. P; MATE, K. E; MAGIN, P. J et al.Journal of clinical pharmacy and therapeutics (Print). 2014, Vol 39, Num 4, pp 383-389, issn 0269-4727, 7 p.Article

CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid controlKITZMILLER, Joseph Paul; SULLIVAN, Danielle M; PHELPS, Mitchell A et al.Drug metabolism and drug interactions. 2013, Vol 28, Num 1, pp 59-63, issn 0792-5077, 5 p.Article

Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction PotentialGERTZ, Michael; CARTWRIGHT, Catherine M; HOBBS, Michael J et al.Pharmaceutical research. 2013, Vol 30, Num 3, pp 761-780, issn 0724-8741, 20 p.Article

Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidineGRÜN, Barbara; MERKEL, Ulrike; RIEDEL, Klaus-Dieter et al.British journal of clinical pharmacology. 2012, Vol 74, Num 5, pp 854-863, issn 0306-5251, 10 p.Article

Effect of Ketoconazole on the Pharmacokinetics of the Dipeptidyl Peptidase-4 Inhibitor Teneligliptin: An Open-Label Study in Healthy White Subjects in GermanyNAKAMARU, Yoshinobu; HAYASHI, Yoshiharu; SEKINE, Mana et al.Clinical therapeutics. 2014, Vol 36, Num 5, pp 760-769, issn 0149-2918, 10 p.Article

Identification and Characterization of a Defective CYP3A4 Genotype in a KidneyTransplant Patient With Severely Diminished Tacrolimus ClearanceWERK, A. N; LEFELDT, S; HEEMANN, U et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 4, pp 416-422, issn 0009-9236, 7 p.Article